19 dec: DK/Sydbank: Stærk krone sender Nationalbanken i arbejdstøjet
19 dec: Aktier/middag: Nets og Pandora topper glansløst marked
19-12-2016 10:52:01

Financial calendar for 2017

Relateret indhold
09 aug - 
KORR: Zealand Pharma er nu dobbeltnoteret i Danmark og ..
09 aug - 
Zealand Pharma er nu dobbeltnoteret i Danmark og USA
09 aug - 
Zealand vil rejse en halv milliard ved børsnotering i U..
Relateret debat
18:22 - 
Er "udbytte" ikke bare et andet ord for "at fodre hunde..
17:02 - 
Hvad mener du med det? Du betaler samme skat af dit udb..
15:47 - 
Forstå dg kke helt.   Tager du f.eks 5000 ak..

Company announcement - No. 50 / 2016

Financial calendar for 2017

Copenhagen, 19 December 2016 - Zealand Pharma ("Zealand") announces the following dates for the company's planned financial reporting in 2017:

15 March         Full year announcement and Annual Report 2016       

17 May            Interim report for 1st quarter 2017

24 August        Interim report for 1st half 2017

8 November     Interim report for the first 9 months of 2017

Zealand's Annual General Meeting for 2017 will be held on 5 April 2017.

                                                                                                                                        

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe). 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

50-16_1219 Financial calendar 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 775709.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 aug
ZEAL
Jeg mener kun jeg har set at de har ansøgt men nu ser det ud til at de har fået svar.   Zealand Phar..
11
14 aug
ZEAL
Tænk Hvad i 2 ikke kunne udrette hvis i blot brugte jeres tid på noget fornuftigt?
8
16 aug
ZEAL
Du kan omvendt argumentere at der er har været en "rabat" på at der var en frygt knyttet til at man ..
3
14 aug
ZEAL
Det hedder stadig ikek en IPO, for det hedder det kun foerste gang et firma gaar paa boersen....... ..
3
14 aug
ZEAL
Company announcement - No. 35/2017     Zealand Pharma A/S has today registered a capital increase o..
3
12 aug
ZEAL
At Soliqus er markedsleder med kombinationsproduktet Soliqua kan ingen vist betvivle.    Zealand Pha..
3
12 aug
ZEAL
Soliqua er stadig markedsleder med kombinationsprodukterne fra Novo og Sanofi selvom godkendelsen af..
3
00:43
ZEAL
Hvis ....................................................... men jeg sagde jo netop at kroppen bruge..
2
17 aug
ZEAL
Godt set at Zealand Pharma har mulighed for at opnå en FDA voucher som den som Sanofi brugte på Soli..
2
17 aug
ZEAL
Alpehue - Disse FDA programmer er jo netop lavet fordi det ikke er lige så attrativt at udvikle denn..
2

Aktier/åbning: Novo tager bundplacering i rødt marked

18-08-2017 09:18:37
Det danske C20 Cap-indeks fortsætter de negative tendenser fra USA og Asien og åbner med et fald på 0,6 pct. i et overvejende rødt marked, hvor særligt Novo Nordisk skiller sig negativt ud.Eliteindekset følger altså uroen fra de tre store amerikanske aktieindeks, Dow Jones, S&P 500 og Nasdaq, som torsdag dykkede markant for anden gang på tre dage, samt de asiatiske markeder, der ligeledes overveje..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Fald i vente efter terror og Trump-tvivl
2
Efter våd sommer: Nu er højsæsonen for dårlige afkast over os
3
Aktier/åbning: Novo tager bundplacering i rødt marked
4
Aktier/middag: Rebound til Vestas og ISS og endnu højere kurs til GN
5
Siemens Gamesa afskediger 600 medarbejdere på vingefabrik i Aalborg

Relaterede aktiekurser

Zealand Pharma A/S 114,50 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. august 2017 18:31:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170808.1 - EUROWEB4 - 2017-08-18 18:31:39 - 2017-08-18 18:31:39 - 1 - Website: OKAY